neurogene.com (NGNE): שווי פעילות לרווח לפני ריבית, מסים ופחת

This EV/EBITDA chart on the GURU.Markets platform is fixed at 0.00. The Neurogene Inc. (NGNE) business relies on the creation of gene therapies that require highly complex temperature-controlled transportation and reliable supply chains. Technological development is driven through alliances with academic institutions to assist critically ill children. Meanwhile, robust patent protection and stringent regulatory requirements create significant barriers to entry for new players.

Neurogene Inc. (NGNE) is facing supply chain disruptions during international gene therapy trials due to geopolitical fragmentation. Fluctuations in the EV/EBITDA multiple reflect the impact of these external risks on the business's market value relative to its operating profit. This metric compares the total value of the company, including debt and taxes, with its ability to generate cash flow. A decline in this metric signals that the asset is undervalued, provided the operating margin remains stable.